Rapid Medical’s Drivewire 24 Platform Used in Initial Neurovascular Procedures

July 22, 2024—Rapid Medical announced that the first commercial cases in the United States were conducted with the company’s Drivewire 24 deflectable access platform after receiving FDA clearance for the device. The procedures were performed by Shahram Majidi, MD, of Mount Sinai Health System in New York, New York.

The company stated that the Drivewire device is designed to provide high-performance intravascular steering. With its active technology, Drivewire articulates a wide range of catheters for direct access to endovascular locations.

According to Rapid Medical, interventionists can control the direction and shape of the guidewire tip in real time, eliminating the need to remove the wire to reshape it. The device also features variable support to articulate a wide range of micro and intermediate catheters without advanced forerun or additional support devices. This aims to provide precise navigation via the most direct route through the neuro and peripheral vasculature.

In the procedures performed by Dr. Majidi, the Drivewire 24 navigated the aspiration catheter directly to the M2 arterial occlusion for first-pass excellent reperfusion. In the second case, Drivewire navigated complex turns to place two flow diverters in a large, multilobed aneurysm, noted the company.

“Drivewire addresses a major unmet need in the endovascular space,” commented Dr. Majidi in Rapid Medical’s press release. “It transforms access across a range of procedures, from aneurysms to strokes and more. We’re always looking for devices to make procedures faster, safer, less expensive. My first experience with Drivewire suggests it could do all of these.”

Rapid Medical announced the procedures at the Society of NeuroInterventional Surgery’s 21st annual meeting held July 22-26 in in Colorado Springs, Colorado.